Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phibro Animal Health (PAHC) Common Equity (2016 - 2025)

Phibro Animal Health (PAHC) has 13 years of Common Equity data on record, last reported at $332.4 million in Q4 2025.

  • For Q4 2025, Common Equity rose 34.67% year-over-year to $332.4 million; the TTM value through Dec 2025 reached $332.4 million, up 34.67%, while the annual FY2025 figure was $285.7 million, 11.32% up from the prior year.
  • Common Equity reached $332.4 million in Q4 2025 per PAHC's latest filing, up from $311.7 million in the prior quarter.
  • Across five years, Common Equity topped out at $332.4 million in Q4 2025 and bottomed at $215.9 million in Q1 2021.
  • Average Common Equity over 5 years is $265.7 million, with a median of $266.5 million recorded in 2022.
  • Peak YoY movement for Common Equity: dropped 9.16% in 2024, then skyrocketed 34.67% in 2025.
  • A 5-year view of Common Equity shows it stood at $239.3 million in 2021, then rose by 12.15% to $268.4 million in 2022, then rose by 0.91% to $270.8 million in 2023, then dropped by 8.86% to $246.8 million in 2024, then soared by 34.67% to $332.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Common Equity were $332.4 million in Q4 2025, $311.7 million in Q3 2025, and $285.7 million in Q2 2025.